Skip to content
Disclosery

Ally Bridge Group (NY) LLC

Follow

13F filer, CIK 1822947, NEW YORK, NY

Ally Bridge Group (NY) LLC reported $95,990,877 across 18 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17. Its ten largest share positions make up 90.45% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-055035

Period
2025-12-31
Reported value
$96M
Holdings
18
Top 10 weight
90.45%
New
10
Sold out
16

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ABVXnew+70,000$9.44M
IVAnew+1,500,000$6.97M
NERVnew+1,655,500$6.66M
PRAXnew+19,882$5.86M
EWTXnew+195,000$4.84M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MDGLexited-32,662-$15M
ASNDexited-51,080-$10.2M
LENZexited-175,363-$8.17M
TSHAreduced-1,440,980-$7.93M
SLNOreduced-134,454-$6.23M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001193125-26-055035, largest first. % of portfolio is the value over $62,997,127, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 70,000 shares 70,000$9.44M14.98%newTimeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 87,629 shares; 2025Q1: 120,449 shares; 2025Q2: 178,819 shares; 2025Q3: 302,483 shares; 2025Q4: 168,029 shares 168,029$7.78M12.35%-134,454Timeline
ATAIBECKLEY INCATAIBECKLEY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,287,005 shares; 2025Q4: 1,713,105 shares 1,713,105$7.01M11.12%-573,900
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,500,000 shares 1,500,000$6.97M11.07%newTimeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,655,500 shares 1,655,500$6.66M10.56%newTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 73,185 shares; 2024Q4: 44,982 shares; 2025Q1: 95,582 shares; 2025Q2: 80,880 shares; 2025Q3: not reported; 2025Q4: 19,882 shares 19,882$5.86M9.3%newTimeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 187,695 shares; 2024Q4: 83,176 shares; 2025Q1: 102,650 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 195,000 shares 195,000$4.84M7.68%newTimeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 915,000 shares; 2025Q4: 397,895 shares 397,895$3M4.77%-517,105Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,785,000 shares 1,785,000$2.91M4.62%newTimeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,898,112 shares; 2025Q4: 457,132 shares 457,132$2.51M3.99%-1,440,980Timeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 724,000 shares; 2025Q3: 549,182 shares; 2025Q4: 413,625 shares 413,625$2.33M3.7%-135,557Timeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 817,939 shares; 2025Q1: 817,939 shares; 2025Q2: 817,939 shares; 2025Q3: 817,939 shares; 2025Q4: 817,939 shares 817,939$1.98M3.14%0Timeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 249,339 shares 249,339$1.7M2.7%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
REPLREPLIMUNE GROUP INC COMMON STOCKcall1,200,000$11.7M-2,400,000
CMPSCOMPASS PATHWAYS PLC SPONSORED ADScall1,100,000$7.59M-45,700
EWTXEDGEWISE THERAPEUTICS INC COMput250,000$6.2Mnew
QUREUNIQURE NV SHScall200,000$4.79Mnew
TSHATAYSHA GENE THERAPIES INC COMMON STOCKcall500,000$2.75Mnew

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SLNOSOLENO THERAPEUTICS INC250,000$16.9Mcall
MDGLMADRIGAL PHARMACEUTICALS INC32,662$15Mshares
ASNDASCENDIS PHARMA A/S51,080$10.2Mshares
LENZLENZ THERAPEUTICS INC175,363$8.17Mshares
AMLXAMYLYX PHARMACEUTICALS INC437,391$5.94Mshares
CMPSCOMPASS PATHWAYS PLC1,026,382$5.88Mshares
PRAXPRAXIS PRECISION MEDICINES I100,000$5.3Mcall
MNPRMONOPAR THERAPEUTICS INC64,455$5.26Mshares
ARQTARCUTIS BIOTHERAPEUTICS INC233,220$4.4Mshares
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INC361,444$4.26Mshares
TARSTARSUS PHARMACEUTICALS INC70,778$4.21Mshares
PROMIS NEUROSCIENCES INCPROMIS NEUROSCIENCES INC6,233,497$2.65Mshares
AVTXAVALO THERAPEUTICS INC178,100$2.26Mshares
TECXTECTONIC THERAPEUTIC INC138,595$2.17Mshares
MLTXMOONLAKE IMMUNOTHERAPEUTICS69,000$495Kcall
ATYRATYR PHARMA INC600,000$433Kcall

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-055035 base2026-02-17acceptance time not in the bulk data set